Inhibrx Biosciences (INBX) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Inhibrx Biosciences (INBX) has outperformed Vor Biopharma (VOR) over the past year, gaining 176.0% versus a loss of 42.7%. Inhibrx Biosciences is the larger company by market cap ($1.37 billion vs $1.13 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | VOR |
|---|---|---|
| Share price | $92.76 | $19.13 |
| Market cap | $1.37B | $1.13B |
| 1-day change | -0.64% | +1.86% |
| YTD return | +17.42% | +46.25% |
| 1-year return | +175.99% | -42.72% |
| 5-year return | — | -93.93% |
| P/E ratio (TTM) | — | 0.11 |
| EPS (TTM) | $-8.88 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $155.29 | $33.50 |
| 52-week low | $28.16 | $6.50 |
| Distance from 52-week high | -40.27% | -42.90% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +187.48% | +103.87% |
| Average volume | 284.58K | 989.57K |
| Shares outstanding | 14.72M | 59.16M |
| Employees | 109 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INBX has outperformed VOR by 218.7 percentage points over the past year.
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
INBX vs VOR FAQ
Which is bigger, Inhibrx Biosciences or Vor Biopharma?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.37B compared with $1.13B for Vor Biopharma (VOR).
Which stock has performed better over the past year, INBX or VOR?
INBX returned +175.99% over the past 12 months, compared with -42.72% for VOR (price return, excluding dividends). Past performance does not predict future results.
Are Inhibrx Biosciences and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.